(Q38557519)

4 September 2017

title

Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates (English)

1 reference

4 September 2017

Ola M Saad

1

1 reference

4 September 2017

Ben-Quan Shen

2

1 reference

4 September 2017

Keyang Xu

3

1 reference

4 September 2017

S Cyrus Khojasteh

4

1 reference

4 September 2017

Sandhya Girish

5

1 reference

4 September 2017

Surinder Kaur

6

1 reference

4 September 2017

publication date

1 July 2015

1 reference

4 September 2017

1 reference

4 September 2017

volume

7

1 reference

4 September 2017

issue

13

1 reference

4 September 2017

page(s)

1583-1604

1 reference

Paul Ehrlich's magic bullet concept: 100 years of progress

4 September 2017

cites work

1 reference

Antibody-drug conjugates for the treatment of cancer

21 January 2018

1 reference

Antibody-drug conjugates: present and future.

21 January 2018

1 reference

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

21 January 2018

1 reference

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

21 January 2018

1 reference

FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer

21 January 2018

1 reference

Maturing antibody-drug conjugate pipeline hits 30.

21 January 2018

1 reference

An FDA oncology analysis of antibody-drug conjugates

21 January 2018

1 reference

An industry perspective on tiered approach to the investigation of metabolites in drug development.

21 January 2018

1 reference

Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions

21 January 2018

1 reference

Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges

21 January 2018

1 reference

Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics

21 January 2018

1 reference

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats

21 January 2018

1 reference

Effects of charge on antibody tissue distribution and pharmacokinetics.

21 January 2018

1 reference

Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates

21 January 2018

1 reference

Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper

21 January 2018

1 reference

Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics

21 January 2018

1 reference

Arming antibodies: prospects and challenges for immunoconjugates

21 January 2018

1 reference

Linker technologies for antibody-drug conjugates

21 January 2018

1 reference

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

Methods for site-specific drug conjugation to antibodies

21 January 2018

1 reference

Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes

21 January 2018

1 reference

Site-specific chemical modification of antibody fragments using traceless cleavable linkers

21 January 2018

1 reference

Site-specific antibody drug conjugates for cancer therapy

21 January 2018

1 reference

Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany

21 January 2018

1 reference

Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development

21 January 2018

1 reference

Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs

21 January 2018

1 reference

The cryptophycins as potent payloads for antibody drug conjugates

21 January 2018

1 reference

PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine

21 January 2018

1 reference

2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 - hybrid LBA/LCMS, ELN & regulatory agencies' input).

21 January 2018

1 reference

An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.

21 January 2018

1 reference

Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling

21 January 2018

1 reference

Innovative native MS methodologies for antibody drug conjugate characterization: High resolution native MS and IM-MS for average DAR and DAR distribution assessment.

21 January 2018

1 reference

Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding

21 January 2018

1 reference

IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G.

21 January 2018

1 reference

Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion

21 January 2018

1 reference

Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG.

21 January 2018

1 reference

Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum.

21 January 2018

1 reference

Detecting low level sequence variants in recombinant monoclonal antibodies

21 January 2018

1 reference

Characterization of therapeutic antibodies and related products.

21 January 2018

1 reference

Large-scale identification of ubiquitination sites by mass spectrometry

21 January 2018

1 reference

Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry

21 January 2018

1 reference

In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap

21 January 2018

1 reference

Characterization of antibody drug conjugate positional isomers at cysteine residues by peptide mapping LC-MS analysis.

21 January 2018

1 reference

Automated approach for quantitative analysis of complex peptide mixtures from tandem mass spectra

21 January 2018

1 reference

Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis

21 January 2018

1 reference

Stable isotope-resolved metabolomics and applications for drug development

21 January 2018

1 reference

Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection

21 January 2018

1 reference

Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data

21 January 2018

1 reference

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

21 January 2018

1 reference

Contribution of linker stability to the activities of anticancer immunoconjugates

21 January 2018

1 reference

The role of in vitro ADME assays in antimalarial drug discovery and development

21 January 2018

1 reference

Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?

21 January 2018

1 reference

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.

21 January 2018

1 reference

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

21 January 2018

1 reference

The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates

21 January 2018

1 reference

Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies

21 January 2018

1 reference

Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).

21 January 2018

1 reference

Fabrication of an on-line enzyme micro-reactor coupled to liquid chromatography-tandem mass spectrometry for the digestion of recombinant human erythropoietin.

21 January 2018

1 reference

The role of protein and peptide separation before mass spectrometry analysis in clinical proteomics

21 January 2018

1 reference

Early human ADME using microdoses and microtracers: bioanalytical considerations

21 January 2018

1 reference

Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/BIO.15.87

1 reference

release_4llhp4x6zfa5lk2nzmvvmxwllu

4 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4llhp4x6zfa5lk2nzmvvmxwllu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference